NIDR and NCI Establish Four Research Centers for Oral Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 11
Volume 5
Issue 11

BETHESDA, Md-With the aim of increasing oral cancer survival rates, the National Institute of Dental Research (NIDR) and the National Cancer Institute will jointly fund four research centers to investigate the causes of oral cancers and to develop improved treatments.

BETHESDA, Md—With the aim of increasing oral cancer survival rates, the National Institute of Dental Research (NIDR) and the National Cancer Institute will jointly fund four research centers to investigate the causes of oral cancers and to develop improved treatments.

The four centers will receive a total of $2.8 million during fiscal 1997 and additional funds in the following 4 years. They will be located at the University of Alabama at Birmingham; the University of California, San Francisco; the University of Chicago and Northwestern University; and the University of Texas M.D. Anderson Cancer Center.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
1 expert is featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
5 experts are featured in this series
5 experts are featured in this series
2 experts in this video
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
2 experts in this video
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content